| Literature DB >> 33437635 |
Yongchun Zhou1,2,3,4, Shanshan Xie1,3,4, Yifu Tang1,3,4, Xiaoning Li1,3,4, Yong Cao5,3,4, Jianzhong Hu5,3,4, Hongbin Lu1,3,4.
Abstract
BACKGROUND: Tissue engineering has exhibited great effect on treatment for bone-tendon interface (BTI) injury. The aim of this study was to evaluate the effect of a book-shaped acellular tendon scaffold (ATS) with bone marrow mesenchymal stem cells sheets (MSCS) for BTI injury repair.Entities:
Keywords: Bone marrow mesenchymal stem cell sheets; Book-shaped acellular tendon scaffold; Patella-patellar tendon interface; Regeneration; Tissue engineering
Year: 2020 PMID: 33437635 PMCID: PMC7773951 DOI: 10.1016/j.jot.2020.02.013
Source DB: PubMed Journal: J Orthop Translat ISSN: 2214-031X Impact factor: 5.191
Reverse transcription–polymerase chain reaction primer sequences.
| Genes | Forward primer sequences | Reverse primer sequences |
|---|---|---|
| GAPDH | ATGGTGAAGGTCGGAGTGAA | GCAAACCTTCTCAAACTCGCCCAC |
| Sox-9 | CGCCCCCGCTAGCCGCACGA | CTGGTGCTCCGCGTAGTCGAACTG |
| Aggrecan | CCCAACTGCGGCGGAAACCT | ATGTCCTCCTCACCGCCCACTCC |
| Tenomodulin | CCATGCTGGATGAGAGAGGTT | CCGTCCTCCTTGGTAGCAGT |
| Alpha-1 type I collagen | ATGGATTCCAGTTCGAGTAGGC | CATCGACAGTGACGCTGTAGG |
Figure 1The diagrammatic drawing of the preparation of MSCS and the combination of MSCS and ATS. ATS = acellular tendon scaffold; MSCS = mesenchymal stem cells sheet.
Figure 2(A) Macroscopic features of the book-shaped acellular tendon scaffold; (B) H&E staining of the native and acellular book-shaped tendon scaffold; (C) DAPI staining of the native and acellular book-shaped tendon scaffold; (D) SEM observation of the native and acellular book-shaped tendon scaffold. H&E = haematoxylin and eosin; DAPI, 4’,6-diamidino-2-phenylindole; SEM = scanning electron microscope.
Figure 3(A,B) Analysis of gene expression involving tenogenic differentiation; (C, D) analysis of gene expression involving chondrogenic differentiation. Different letters represent statistical significant difference, p < 0.05. ATS = acellular tendon scaffold; TNMD = Tenomodulin; ACAN = Aggrecan.
Figure 4The area of new bone of regenerated patella–patellar tendon interface at 8 and 16 weeks postoperatively: (A) Representative H&E staining images; (B) semiquantitative analysis of the area of new bone. Scale bars = 100 μm. aSignificantly different from the control group at the same time point postoperatively, p < 0.05; bStatistically significant difference between the ATS group and the ATS+ MSCS group at the same time point postoperatively, p < 0.05; cStatistical difference between 8 and 16 weeks postoperatively in the same group, p < 0.05. The dotted line shows the osteotomy site. ATS = acellular tendon scaffold; MSCS = mesenchymal stem cells sheet; NB = newly formed bone; RP = remaining patella; TF = tendon fibre.
Figure 5The regenerated fibrocartilage of regenerated patella–patellar tendon interface at 8 and 16 weeks postoperatively: (A) Representative toluidine blue staining images; (B) semiquantitative analysis of the thickness of the regenerated fibrocartilage layer. Scale bars = 600 μm aSignificantly different from the control group at the same time point postoperatively, p < 0.05; bStatistical difference between the ATS group and the ATS+ MSCS group at the same time point postoperatively, p < 0.05; cStatistical difference between 8 and 16 weeks postoperatively in the same group, p < 0.05. ATS, acellular tendon scaffold; FC, fibrocartilage; MSCS, mesenchymal stem cells sheet; NB = newly formed bone; TF = tendon fibre.
Figure 6The expression of CD206 at regenerated patella–patellar tendon interface at 2, 4, 8 and 16 weeks postoperatively: (A) IF staining images of representative CD206+ macrophages; (B) semiquantitative analysis of CD206+ macrophages. Scale bars = 45 μm. Different letters represent statistical significance, p < 0.05. ATS = acellular tendon scaffold; MSCS = mesenchymal stem cells sheet.
Biomechanical properties of the patella–patellar tendon interface.
| Test item | 8W | 16W | ||||
|---|---|---|---|---|---|---|
| Control group | ATS group | ATS+MSCS group | Control group | ATS group | ATS+MSCS group | |
| Failure Load(N) | 152.62 ± 16.21 | 193.18 ± 9.41 | 229.54 ± 9.65 | 249.38 ± 10.14 | 308.25 ± 22.59 | 389.5 ± 20.47 |
| Ultimate Strength (Mpa) | 3.81 ± 0.82 | 6.21 ± 0.43 | 7.86 ± 0.38 | 5.22 ± 0.42 | 7.31 ± 0.75 | 10.33 ± 0.87 |
| Energy at Failure(J) | 0.27 ± 0.02 | 0.35 ± 0.03 | 0.47 ± 0.02 | 0.61 ± 0.03 | 0.78 ± 0.04 | 0.95 ± 0.03 |
ATS = acellular tendon scaffold; MSCS = mesenchymal stem cells sheet.
Statistical difference between the ATS group and the control group at the same time point postoperatively, p < 0.05.
Statistical difference between the ATS+MSCS group and the control group at the same time point postoperatively, p < 0.05.
Statistical difference between the ATS+MSCS group and the ATS group at the same time point postoperatively, p < 0.05.
Statistical difference between 8 and 16 weeks postoperatively in the same group, p < 0.05.